




Searching News Database: XTENT
HSMN NewsFeed - 9 Jan 2014
Covidien, Lightstone Ventures, New Enterprise Associates Announce Series A Investment in FIRE1
Covidien, Lightstone Ventures, New Enterprise Associates Announce Series A Investment in FIRE1
HSMN NewsFeed - 13 Jan 2010
The Foundry Announces Completion of Series A Financing for Twelfth Company
The Foundry Announces Completion of Series A Financing for Twelfth Company
HSMN NewsFeed - 19 Mar 2009
XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
HSMN NewsFeed - 28 Jan 2009
The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company
The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company
HSMN NewsFeed - 9 Sep 2008
Transcend Medical Announces New President and CEO and Appointment of Chairman of the Board
Transcend Medical Announces New President and CEO and Appointment of Chairman of the Board
HSMN NewsFeed - 31 Jul 2008
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
HSMN NewsFeed - 20 Jun 2008
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
HSMN NewsFeed - 13 May 2008
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
HSMN NewsFeed - 27 Dec 2007
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
HSMN NewsFeed - 22 May 2007
XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
HSMN NewsFeed - 16 May 2006
Xtent CUSTOM I Trial Shows Zero Restenosis, Favorable Late Loss Results at Eight Months
Xtent CUSTOM I Trial Shows Zero Restenosis, Favorable Late Loss Results at Eight Months
HSMN NewsFeed - 15 May 2006
SurModics Provides Hydrophilic Coating on Xtent's Drug-Eluting Stent Delivery System
SurModics Provides Hydrophilic Coating on Xtent's Drug-Eluting Stent Delivery System
HSMN NewsFeed - 17 Feb 2006
Xtent's Drug-Eluting Stent Technology Witnessed Live During Prominent Interventional Meeting in Rome, Italy
Xtent's Drug-Eluting Stent Technology Witnessed Live During Prominent Interventional Meeting in Rome, Italy
Additional items found! 4

Members Archive contains
4 additional stories matching:
XTENT
(Password required)
XTENT
(Password required)